OKYO Pharma Ltd (NASDAQ:OKYO), focused on developing urcosimod for neuropathic corneal pain, announced that Panetta Partners, in which Executive Chairman Gabriele Cerrone has a beneficial interest, purchased 27,051 shares on NASDAQ, increasing his total holding to 10,491,746 shares.
The Markets by Proactive
Go to Proactive UK
Proactive’s coverage of London’s small caps continues on .com